Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises RusForest in connection with bond issue
Mandate

Vinge advises RusForest in connection with bond issue

May 13, 2011

To enable continued expansion within harvesting and sawmilling, RusForest AB is issuing a bond loan. The loan, which has a term of three years, amounts to SEK 500 million with a fixed interest rate of 11 percent per annum. RusForest will be applying for listing of the bonds on the NASDAQ OMX Stockholm.

Vinge’s team consisted of Fabian Ekeblad, Jesper Schönbeck, Sarah Khalil, Christian Granqvist and Andreas Malmberg. Göran Nyström is partner in charge.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026